tazemetostat
Drug data last refreshed 2d ago
TAZVERIK (tazemetostat) is an oral tablet approved by the FDA on January 23, 2020, representing a novel approach to rare hematologic malignancies. The product is currently in its peak lifecycle stage, indicating strong market establishment and commercial maturity. Specific mechanism of action, pharmacologic class, and indication details are not available in the provided data, though the product's orphan disease targeting suggests precision oncology positioning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moTAZVERIK's peak lifecycle stage and specialty indication create opportunities for field-based roles (specialty sales representatives, oncology-focused account managers) and medical affairs positions (medical science liaisons with hematology/oncology expertise). The zero linked job count suggests either recent stability in staffing or data collection gaps; roles emphasizing rare disease expertise, investigator relationship management, and precise patient identification would be most relevant. Critical skills include knowledge of hematologic malignancy treatment paradigms, strong scientific communication with academic centers, and understanding of specialty pharmacy distribution channels.